康哲药业(00867.HK)获改良型新药ZUNVEYL独家权利

阿斯达克财经
08 Jan

康哲药业(00867.HK) 公布,与Alpha就用于治疗轻度至中度阿尔茨海默型痴呆症状的改良型新药ZUNVEYL签订许可、合作与经销协议,据此,集团获得在亚洲、澳洲、新西兰开发、注册、生产、进口、出口和商业化ZUNVEYL的独家权利,合作期限二十年。

2024年7月,ZUNVEYL获得美国食品和药物管理局批准上市用于治疗轻度至中度阿尔茨海默型痴呆症状,属于新一代乙酰胆碱酯酶抑制剂。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-08 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10